{Reference Type}: Evaluation Study
{Title}: Preparation and evaluation of a novel biodegradable long-acting intravitreal implant containing ligustrazine for the treatment of proliferative vitreoretinopathy.
{Author}: Zhang X;Wei J;Ma P;Mu H;Wang A;Zhang L;Wu Z;Sun K;
{Journal}: J Pharm Pharmacol
{Volume}: 67
{Issue}: 2
{Year}: Feb 2015
{Factor}: 4.81
{DOI}: 10.1111/jphp.12327
{Abstract}: <B>OBJECTIVE: </B>It is challenging to deliver the therapeutic drug effectively to the posterior ocular disease location with optimized exposure and long-term effects when treating proliferative vitreoretinopathy (PVR). The objective of this study is to develop a novel biodegradable and long-acting ocular implant for PVR therapy with ligustrazine as the active ingredient.<BR><B>METHODS: </B>The ligustrazine implants were prepared with poly(DL-lactide-co-glycolide) using a hot-melting extrusion. The physicochemical properties of the implants were characterized. The effectiveness of the selected ligustrazine implants was evaluated in a PVR rabbit model. Furthermore, the in-vitro drug release profile and pharmacokinetics were compared, and in-vitro/in-vivo correlations were evaluated.<BR><B>RESULTS: </B>The optimal implants had an ideal zero-order in-vitro drug release profile, which was correlated with the in-vivo drug absorption fraction in the vitreous bodies of the rabbits. The sustained-release ligustrazine implants significantly reduced the development of PVR in the animal model.<BR><B>CONCLUSIONS: </B>Ligustrazine implants can be used to treat posterior ocular disease in rabbit animal models, and it provides more choices for medical research on posterior ocular disease.